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Bidens pilosa L. is an easy-to-grow, widespread, and palatable perennial on earth. Hence, it has traditionally been used as foods and
medicines without noticeable adverse effects. Despite significant advancement in chemical and biological studies of B. pilosa over
the past few years, comprehensive and critical reviews on its anti-diabetic properties aremissing.Thepresent review is to summarize
up-to-date information on the pharmacology, phytochemistry, and toxicology of B. pilosa, in regard to type 1 diabetes and type 2
diabetes from the literature. In addition to botanical studies and records of the traditional use of B. pilosa in diabetes, scientific
studies investigating antidiabetic action of this species and its active phytochemicals are presented and discussed. The structure
and biosynthesis of B. pilosa and its polyynes in relation to their anti-diabetic action and mechanism are emphasized. Although
some progress has beenmade, rigorous efforts are further required to unlock themolecular basis and structure-activity relationship
of the polyynes isolated from B. pilosa before their clinical applications. The present review provides preliminary information and
gives guidance for further anti-diabetic research and development of this plant.
1. Introduction
Diabetes was coined by a Greek physician, Aretaeus of
Cappadocia (30-90 AD), about 2 millennia ago [1]. He first
described this devastating disease with symptoms, such as
constant thirst (polydipsia), excessive urination (polyuria),
and weight loss, which still hold true nowadays [1].The Inter-
national Diabetes Federation (IDF) estimated that diabetes
afflicted 285 million people, 6.4% of the world population,
who were afflicted with diabetes in 2010 and will afflict 439
million people, 7.7% of the world population by 2030 [2].
Over 90% of diabetic patients are diagnosed with type 2
diabetes (T2D) [3, 4] and the rest are diagnosed with type 1
diabetes and others.
Diabetes is a chronic metabolic disease with fatal compli-
cations such as cardiovascular diseases, retinopathy, renopa-
thy, and foot ulcers. The cost of health care associated with
diabetes continues to grow and is a huge economic burden for
afflicted patients and countries. In the states, approximately
17.5 million adults were reported to be receiving treatment for
diabetes, where the estimated cost of diabetes was 174 billion
dollars in 2007 [5].
Despite much progress made on basic and clinical
research into diabetes, this disease has not been cured since
antiquity. Main reasons for this mishap are unmet efficacy
and significant side effect of the drugs. So far, 1200 plants have
been claimed to be remedies for diabetes [6, 7] and one-third
of them have been scientifically evaluated for T2D treatment
[8]. Among them, B. pilosa is commonly used as food and
medicine for humans and animals [9, 10]. It is an easy-to-
grow herb that is globally distributed. The folkloric use of B.
pilosa to treat diabetes has been recorded in America, Africa,
Asia, and Oceania [11]. Accumulating data have shown
the potential of this plant and active compounds to treat
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Table 1: Taxonomy of 𝐵. pilosa [12].
Kingdom Plantae
Division Magnoliophyta
Class Magnoliopsida
Subclass Asteridae
Order Asterales
Family Asteraceae
Genus Bidens
Species Bidens pilosa L.
diabetes. The present review focuses on recent studies on the
botany, anti-diabetic action andmechanism, phytochemistry,
and toxicology of B. pilosa. The information provided here
highlights the possible usefulness of B. pilosa and its isolated
compounds and offers insights into possible future research
directions.
2. Botanical Properties
B. pilosa is believed to have originated in South America and
subsequently spread everywhere on earth [13]. Bidens species
and their varieties bear vernacular names based on their
sticky seeds or prosperous growth [5]. B. pilosa is taxonomi-
cally assigned to theBidens genus, up to 240 species, as shown
in Table 1 [9, 10]. Different varieties are frequently found in B.
pilosa. B. pilosa is an erect, perennial herb widely distributed
from temperate and tropical regions. It has serrate, lobed,
or dissected form of green opposite leaves, white or yellow
flowers, and long narrow ribbed black seeds (Figure 1) [14].
Apart from morphological traits, chemotaxonomical (Figure
2) and molecular characterization (Table 2) is sometimes
helpful in the identification of B. pilosa strains [15].
Despite its preference for full sun and semidry soil, B.
pilosa can grow in arid and barren lands at different altitudes.
Food and Agricultural Organization actively promoted the
culture of B. pilosa in Africa in 1970s due to its fast-growing
advantage [16]. B. pilosa can be propagated via seeds. After
soaking, B. pilosa seeds can germinate in 3 to 4 days [17].
Minimal agricultural techniques are required for B. pilosa
cultivation. B. pilosa is recognized as one of the top worst
weeds worldwide because of its aggressive invasion [18].
Apart from its use as food ingredient, B. pilosa is used
as herbal medicines for diabetes and 40 other diseases [5].
All parts of B. pilosa plant, the whole plant, the aerial parts
(leaves, flowers, seeds, and stems), and/or the roots, fresh or
dried, are used as ingredients in folk medicines. Dry powder,
decoction, maceration, and tincture are usual formulations
for its internal as well as external use [19]. B. pilosa can be
used alone or together with other medicinal herbs.
3. Antidiabetic Properties
B. pilosa has a variety of pharmacological actions. As far as
its anti-diabetic activity is concerned, B. pilosa and its anti-
diabetic polyynes have been reported to effectively prevent
and treat type 1 diabetes and type 2 diabetes, which are
etiologically distinct [15, 20–24]. In this section, we will focus
Table 2: Percent differences between the internal transcribed spacer
1 (ITS1) regions of the DNA sequences of 𝐵. pilosa variants (BPR,
𝐵. pilosa var. radiata; BPM, 𝐵. pilosa var. minor; and BPP, 𝐵. pilosa
var. pilosa), 𝐵. hintonii, and 𝐵. biternata.
ITS1 BPM BPP BPR BHa BBb
BPM 0 0.39 3.56 4.74 11.37
BPP 0.39 0 3.16 4.45 11.46
BPR 3.56 3.16 0 5.93 12.55
BHa 4.74 4.35 5.93 0 14.45
BBb 11.37 11.46 12.55 14.45 0
aITS1 obtained from GeneBank Accession Number AF330101.1.
bITS1 obtained from GeneBank Acession Number EU117248.1.
our review on the pharmacological action and mechanism of
B. pilosa extract and its active phytochemicals against both
types of diabetes.
3.1. Action and Mechanism of B. pilosa for Type 1 Diabetes.
T1D is caused by the autoimmune destruction of pancreatic 𝛽
cells, leading to insulin deficiency, hyperglycemia, and com-
plications. Monotherapy (immune intervention and 𝛽-cell
replacement/(re)generation) and their combination therapy
are common approaches to treat T1D. Despite considerable
advances made on these approaches, there has no cure
for T1D. Helper T (Th) cell differentiation regulates T1D
development. Further, Th1 cell differentiation promotes T1D,
whereas Th2 cell differentiation alleviates T1D [25].
To test the immunomodulatory effect of B. pilosa, one
study showed that B. pilosa extract and its butanol fraction
could decrease Th1 cells and cytokines and increase Th2
cells and cytokines [23]. This study indicated that IC
50
value of the butanol fraction was 200 𝜇g/mL. This inhibition
was reported to be partially attributed to cytotoxicity,
because the butanol fraction at 180 𝜇g/mL could cause 50%
death of Th1 cells. Using the bioactivity-directed isolation
and identification approach (Figure 3), 3 active polyynes,
3-𝛽-D-glucopyranosyl-1-hydroxy-6(E)-tetradecene-8,10,12-
triyne (17), 2-𝛽-D-glucopyranosyloxy-1-hydroxy-5(E)-tride-
cene-7,9,11-triyne (16), and 2-𝛽-D-glucopyranosyloxy-1-
hydroxytrideca-5,7,9,11-tetrayne (cytopiloyne, 19), as well as
2 index compounds, 4,5-Di-O-caffeoylquinic acid, 3,5-Di-O-
caffeoylquinic acid, and 3,4-Di-O-caffeoylquinic acid, were
isolated from the butanol extract using high pressure liquid
chromatography (HPLC) and, in turns, were structurally
identified by nuclear magnetic resonance (NMR) [23, 24].
Only the first three active compounds showed similar effects
on Th cell differentiation as the B. pilosa butanol fraction.
Moreover, compound 19 showed greater activity than com-
pounds 17 and 16 in terms of enhancement (by 277% com-
pared to 34% and 8%) of differentiation of Th0 to Th2 at
10 𝜇g/mL and inhibition (by 60% compared to 17% and 9%)
of differentiation to Th1 at the same concentration (Table 3)
[23, 24].
Accordingly, the butanol fraction of B. pilosa effectively
prevented T1D in nonobese diabetic (NOD) mice [23]. Con-
sistently, this prevention involved downregulation ofTh1 cells
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Figure 1: Image of B. pilosa (a) and its flowers (b) and seeds (c).
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Figure 2: Chemotaxonomical comparison of three B. pilosa variants (BPR, B. pilosa var. radiata; BPM, B. pilosa var.Minor, and BPP, B. pilosa
var. pilosa). Gas chromatography/mass spectrometry (GC/MS) and cluster analysis to assist in determining the taxonomy of 4 samples of the
three Bidens variants.
or upregulation of Th2 cells. This was proven by intraperi-
toneal injection of the butanol fraction at a dose of 3mg/kg
body weight (BW), 3 times a week, to NOD mice from 4
to 27 weeks [23]. This dosage resulted in lower incidence of
diabetes (33%). At a dose of 10mg/kg, the butanol fraction
of B. pilosa totally stopped (0%) the initiation of the disease
[23]. Th1 cytokine IFN𝛾 and Th2 cytokine IL-4 favor the
production of IgG2a and IgE, respectively. To further confirm
whether this butanol in vivo regulated Th cell differentiation
and Th cytokine profiling, IgG2a and IgE production was
measured in the serumofNODmice. As expected, high levels
of IgE and some decline in the levels of IgG2a were observed
in the serum [23].
Since cytopiloyne (19) had the most potent effect on
Th cell differentiation among the aforesaid polyynes [20],
another study used cytopiloyne to explore the action and
molecular mechanism of cytopiloyne on T1D in NOD mice
[20]. NOD mice received intraperitoneal or intramuscular
injection of cytopiloyne at 25 𝜇g/kg BW, 3 times per week.
Twelve-week-old NOD mice started to develop T1D, and
70% of NOD mice aged 23 weeks and over developed
T1D. Remarkably, 12- to 30-week-old NOD mice treated
with cytopiloyne showed normal levels of blood glucose
(<200mg/dL) and insulin (1-2 ng/mL). Consistent with T1D
incidence, cytopiloyne delayed and reduced the invasion
of CD4+ T cells into the pancreatic islets [20]. Albeit
4 Evidence-Based Complementary and Alternative Medicine
Bioactive 
compound(s)
BDFIScreening platform:
Th cell differentiation
Crude 
extract
(a)
Th0
Th2
Phytocompound
Th1
PHA + IL-12 + 𝛼-IL4
PHA + IL-4 + 𝛼-IL12
IFN𝛾-producing cells
IL-4-producing cells
(b)
O
OH
OH OH
HO HO HO
HO
HO HO
HO
HO HO HO
HO HO
O
O O
16 19
O
O
17
Retention time (min)
Re
l a
bs
 (%
)
0 5 10 15 20 25 30 35
0
80
20
40 16
19
17
(c)
Figure 3: Bioactivity-directed fractionation and isolation approach to identify three active polyynes that regulate Th cell differentiation.
A flowchart of the bioactivity-directed fractionation and isolation (BDFI) strategy describes the use of the screening platform and Th cell
differentiation assays to determine bioactive compounds from the crude extract and fractions of B. pilosa (a). Bioassays are composed of
human na¨ıve helper T cells (Th0) which can differentiate into type 1 helper T (Th1) cells and type 2 helper T (Th2) cells in the presence of
PHA plus IL-12 and anti-IL-4 antibody and PHAwith IL-4 and anti-IL-12 antibody, respectively.The crude extract, fractions, and compounds
ofB. pilosa are added to differentiating cells to test theThcell differentiation (b). Compounds 16, 17, and 19 are active compounds that promote
Th2 cell differentiation but inhibit Th1 cell differentiation.
Table 3: Th1 inhibition andTh2 promotion by the extract (150 𝜇g/mL) and polyynes (10𝜇g/mL) of 𝐵. pilosa.
Butanol extract Compound 19 Compound 17 Compound 16
Reduction of Th1 (%) 32% 75% 17% 9%
Increase of Th2 (%) 103% 277% 31% 6%
less effective than cytopiloyne (19), 3-𝛽-D-glucopyranosyl-
1-hydroxy-6(E)-tetradecene-8,10,12-triyne (17), and 2-𝛽-D-
glucopyranosyloxy-1-hydroxy-5(E)-tridecene-7,9,11-triyne (16)
also decreased T1D development in NODmice.
The underlying mechanism by which cytopiloyne and
its derivatives inhibited T1D covered inactivation of T cells,
polarization of Th cell differentiation, and Th cell deple-
tion, leading to islet protection [20] and is illustrated in
Figure 4. First, [3H] thymidine incorporation assay showed
that cytopiloyne inhibited ConA/IL-2- and CD3 antibody-
mediatedT cell proliferation, implying that cytopiloyne could
inhibit T cell activation. Second, in vitro study showed that
cytopiloyne (19) inhibited the differentiation of na¨ıve Th
(Th0) cells (i.e., CD4+ T cells) into Th1 cells and promoted
differentiation of Th0 cells into Th2 cells [24]. The in vitro
data are consistent with the in vivo results, indicating that
cytopiloyne reduced Th1 differentiation and increased Th2
differentiation as shown by intracellular cytokine staining
and FACS analysis [20]. Cytopiloyne also enhanced the
expression of GATA-3, a master gene for Th2 cell differen-
tiation, but not the expression of T-bet, a master gene for
Th1 cell differentiation, further supporting its role in skew-
ing Th differentiation [20]. In line with the skewing of Th
differentiation, the level of serum IFN-𝛾 and IgG2c decreased,
while that of serum IL-4 and serum IgE increased com-
pared to the negative controls (PBS-treated mice). Third,
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Figure 4: The underlying mechanism of the crude extract of B. pilosa (BP) and its active compound, compound 19 (CP), in T1D. BP and/or
CP can suppress T1D development via regulation of T cells (A andB) and 𝛽 cells (C) in NOD mice (a). Their regulation of T cells involves
Th cell activation and differentiation (A) and partial depletion of Th0 cells (B) as depicted (b). CP and/or BP augment the expression of
GATA-3 gene and, in turn, promote the expression of IL-4 andTh2 cell differentiation. In contrast, CP and/or BP do not affect the expression
of T-bet (c).
cytopiloyne partially depleted CD4+ rather than CD8+ T
cells in NOD mice [20]. Coculture assays showed that the
depletion of CD4+ T cells was mediated through the induc-
tion of Fas ligand expression on pancreatic islet cells by
cytopiloyne, leading to apoptosis of infiltrating CD4+ T cells
in the pancreas via the Fas and Fas ligand pathway. However,
cytopiloyne did not induce the expression of TNF-𝛼 in pan-
creatic islet cells and, thus, had no effect on CD8+ T cells [20].
Due to the antidiabetic mechanisms of action, it was
hypothesized that cytopiloyne protects NOD mice from
diabetes by a generalized suppression of adaptive immunity.
To evaluate this hypothesis, ovalbumin (Ova) was used as
a T-cell dependent antigen to prime NOD mice, which had
already received cytopiloyne or PBS vehicle. Ova priming
enhanced similar anti-Ova titers in cytopiloyne-treated mice
and PBS-treated mice, but a different profile of immunoglob-
ulin isotype was observed in the two groups. Therefore, it
was concluded that cytopiloyne is an immunomodulatory
compound rather than an immunosuppressive compound
[20, 24].
Collectively speaking, themechanism of action of cytopi-
loyne and, probably, its polyyne derivatives in T1D includes
inhibition of T-cell proliferation, skewing of Th cell differen-
tiation and partial depletion of Th cells, and protection of 𝛽
pancreatic islets.
3.2. Action and Mechanism of B. pilosa for Type 2 Diabetes.
Mounting evidence from epidemiological studies proposes
environmental and genetic factors as the primary causes of
T2D. Both factors contribute to insulin resistance and loss
of 𝛽-cell function, leading to impairment in insulin action,
insulin production, or both. As a result, this impairment
accompanies the development of hyperglycemia, a major
pathological feature of T2D [26]. Hyperglycemia can cause
damage to 𝛽 cells and other peripheral tissues, named gluco-
toxicity. As a consequence, cardiovascular disease, nephropa-
thy, retinal blindness, neuropathy, and peripheral gangrene
develop and contribute to mortality [27]. Therefore, mainte-
nance of glycemic homeostasis has been a golden standard for
T2D therapy.Moreover, aberrant lipidmetabolism in adipose
and other tissues can cause lipotoxicity, which can further
worsen diabetic complications.The 𝛽 cells in the pancreas are
the key players in glycemic homeostasis [28].
Plants are an extraordinary source for anti-diabetic
agents. Over 1200 plant species have be claimed to treat
diabetes [6, 7]. One of them, B. pilosa, has traditionally been
used as an anti-diabetic herb in America, Africa, and Asia
[7, 29, 30]. More recently, B. pilosa has scientifically been
investigated for anti-diabetic activity. One seminal study by
Ubillas et al. showed that the aqueous ethanol extract of the
aerial part of B. pilosa at 1 g/kg BW lowered blood glucose
in db/db mice, a T2D mouse model [30]. They also used
a bioactivity-guided identification strategy to identify two
polyynes, compounds 17 and 16. Moreover, the mixture of
the compounds (17 : 16) in a 2 : 3 ratio significantly reduced
blood glucose level and food intake on the second day
when administered at doses of 0.25 g/kg twice a day to
C5BL/Ks-db/db mice. When evaluated at 0.5 g/kg, a more
substantial decrease in blood glucose level as well as the
stronger anorexia (food intake reduced from 5.8 g/mouse/day
to 2.5 g/mouse/day) was noticed [30]. This study suggested
that compounds 17 and 16 were active ingredients of B. pilosa
for diabetes [30]. The anti-diabetic effect of both polyynes
was partially caused by the hunger suppressing effect.
However, the anoxic effect of the ethanol extract of B. pilosa
was not observed in the studies described below. In another
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study [31], water extracts of B. pilosa (BPWE) were tested in
diabetic db/db mice, aged 6–8 weeks, with postmeal blood
glucose levels of 350 to 400mg/dL. Like oral anti-diabetic
glimepiride, which stimulates insulin release, one-single dose
of BPWE reduced blood glucose levels from374 to 144mg/dL.
The antihyperglycemic effect of BPWE was relevant to an
increase in serum insulin levels, implying that BPWE drops
blood glucose concentration through an upregulation of
insulin production.However, BPWE showed different insulin
secretion kinetics from glimepiride [31]. One drawback in
current anti-diabetic agents is their decreasing efficacy over
time. Therefore, the authors investigated the long-term anti-
diabetic effect of BPWE in db/db mice. BPWE lowered blood
glucose, boosted blood insulin, improved glucose tolerance,
and reduced the percentage of glycosylated hemoglobulin
(HbA1c). Both one-time and long-term experiments strongly
support the superior action of BPWE on diabetes [31]. Unlike
glimepiride, which failed to preserve pancreatic islets, BPWE
was significantly protected against islet atrophy in mouse
pancreas. The group also evaluated anti-diabetic effect of
3 B. pilosa varieties, B. pilosa var. radiate (BPR), B. pilosa
var. pilosa (BPP), and B. pilosa var. minor (BPM) in db/db
mice [15]. A single oral dose (10, 50, and 250mg/kg BW)
of BPR, BPP, or BPM water extracts decreased postprandial
blood glucose levels in db/db mice for up to four hours and
this reduction was dose-dependent. Of note, BPR extract
resulted in a higher reduction in blood glucose levels when
administered at the same dose as the other two varieties.
Further, the BPR extract increased serum insulin levels in
db/db mice to a greater extent than the other varieties at the
same dose, 50mg/kg.Three polyynes, compounds 16, 17, and
19, were identified from the three Bidens strains though their
varied contents. Compound 19 at 0.5mg/kg exerted a better
stimulation for insulin production in db/db mice than com-
pounds 17 and 16. On the contrary, 28-day treatment with
the Bidens extracts and three polyynes were then performed
using diabetic mice with postprandial glucose levels from 370
to 420mg/dL and glimepiride was used as positive control.
The applied dosages ranged from 10mg/kg to 250mg/kg BW.
Results showed that the positive control as well as the crude
extracts of the three varieties lowered the blood glucose
levels in db/db mice. However, only BPR extract, containing
a higher content of cytopiloyne (19), reduced blood glucose
levels and augmented blood insulin levels more than BPP
and BPM. The percentage of glycosylated hemoglobin A1c
(HbA1c), a long-term indicator of blood homeostasis, was
also monitored. HbA1c in the blood of 10- to 12-week-old
diabetic mice was 7.9 ± 0.5%. However, treatment with
BPR crude extract (50mg/kg), glimepiride (1mg/kg), and
compound 19 (0.5mg/kg) led to the HbA1c of 6.6 ± 0.2%,
6.1 ± 0.3%, and 6.2 ± 0.3% in the blood of age-matched
mice, respectively [15]. Since cytopiloyne (19) was the most
effective polyyne found in B. pilosa, against T2D, it was used
for further study on anti-diabetic action and mechanism
in another study [22]. The data confirmed that cytopiloyne
reduced postmeal blood glucose levels, increased blood
insulin, improved glucose tolerance, suppressed HbA1c level,
and protected pancreatic islets in db/db mice. Nevertheless,
cytopiloyne never managed to decrease blood glucose in
streptozocin- (STZ-) treated mice whose 𝛽 cells were already
destroyed. In addition, cytopiloyne dose-dependently
promoted insulin secretion and expression in 𝛽 cells as well
as calcium influx, diacylglycerol, and activation of protein
kinase C𝛼. Taken together, the mechanistic studies suggest
that cytopiloyne acts to treat T2Dvia regulation of𝛽 cell func-
tions (insulin production and 𝛽 cell preservation) involving
the calcium/diacylglycerol/PKC𝛼 cascade (Figure 5).
The above studies point to the conclusion that cytopiloyne
(19) and related polyynes (compounds 16 and 17) are anti-
diabetic agents in animal models. The data unfold a new
biological action of polyynes. However, like all drugs devel-
oped for diabetes, cytopiloyne could neither prevent nor stop
diabetes completely but reduced diabetic complications [22].
Intriguingly, 36 polyynes have been found in B. pilosa so far.
It remains to be investigated whether all the polyynes present
in this plant have anti-diabetic activities.
4. Phytochemistry
Broad application of B. pilosa all over the world has led to
over 120 publications on its exploitation and use inmedicines,
foods, and drinks. B. pilosa is an extraordinary source of
phytochemicals and 201 compounds have so far been identi-
fied from this plant, including 70 aliphatics (36 polyynes), 60
flavonoids, 25 terpenoids, 19 phenylpropanoids, 13 aromatics,
8 porphyrins, and 6 other compounds [32]. Mounting evi-
dence suggests that phytochemical complexity ofB. pilosa can
account for its diverse bioactivities. The structures and likely
bioactivities of these compounds were recently reviewed in
the previous publications [5, 32], which are out of our scope.
In this section, we focus on the chemical structures of 36
polyynes found in B. pilosa (Table 4) and their bioactivities
(Table 5). We also discuss the likely biosynthesis of the
polyynes in B. pilosa. Although their biosynthesis is not
well defined, those polyynes are thought to derive from
desaturation and acetylenation of fatty acids (Figure 6) in B.
pilosa and other plants.
5. Toxicology
Food and Agricultural Organization of the United Nations
has reported B. pilosa as a staple food and promoted its
cultivation in Africa since 1975. Taiwanese Department of
Health also allows its use as an ingredient in food for human
consumption. Despite lack of systemic toxicological study of
B. pilosa in humans, some information about acute and/or
subchronic toxicities was revealed in rodents. Frida and
colleagues reported that one-single oral dose of the water
extract of B. pilosa leaves at 10 g/kg BW showed no obvious
mortality or changes in the appearance of rats [61]. The
same extract at 0.8 g/kg BW/day, once a day, showed no
obvious sub-chronic toxicity in rats over 28 days, as shown by
survival rate, body weight, and gross examination of organs
[61]. They also evaluated the acute toxicity of hydroethanol
extracts of B. pilosa in mice [61]. Five- to six-week-old mice,
weighing between 28 and 35 g, received a peritoneal injection
of both extracts at the different doses. The LD
50
, the dose
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Table 4: Polyynes isolated from 𝐵. pilosa [32].
S.
number IUPAC names Common names Structure
Plant part
(country) References
1
1,7𝐸,9𝐸,15𝐸-
Heptadecatetraene-
11,13-diyne
Heptadeca-
2𝐸,8𝐸,10𝐸,16-tetraen-
4,6-diyne
Not found
(China) [33]
2 1,11-tridecadiene-3,5,7,9-tetrayne
Roots (not
stated) [34]
3 1-Tridecene-3,5,7,9,11-pentayne Pentadiene
Leaves (not
stated) and not
found (Egypt)
[34, 35]
4 5-Tridecene-7,9,11-triyne-3-ol
HO
Not found
(Egypt) [35]
5 2,10,12-Tridecatriene-4,6,8-triyn-1-ol
OH Part not
specified (not
stated)
[36]
6 2,12-Tridecadiene-4,6,8,10-tetrayn-1-ol
1,11-Tridecadiene-
3,5,7,9-tetrayn-13-ol
OH
Roots (not
stated) and not
found (Egypt)
[34, 35]
7 2,12-Tridecadiene-4,6,8,10-tetraynal
1,11-Tridecadiene-
3,5,7,9-tetrayn-13-al
O
Roots
(Germany) [37]
8
2,12-Tridecadiene-
4,6,8,10-tetrayn-1-ol,1-
acetate
1,11-Tridecadiene-
3,5,7,9-tetrayn-13-
acetate
O
O
Roots (not
stated) [34]
9 (5𝐸)-1,5-Tridecadiene-7,9-diyn-3,4,13-triol
OH
OH
HO
Aerial (China) [38]
10
(6𝐸,12𝐸)-3-oxo-
tetradeca-6,12-dien-
8,10-diyn-1-ol
OH
O
Aerial (China) [38]
11 (𝐸)-5-Tridecene-7,9,11-triyne-1,2-diol
1,2-Dihydroxy-5(𝐸)-
tridecene-7,9,11-triyne
HO
OH
Whole (Taiwan) [39]
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12 (𝐸)-6-Tetradecene-8,10,12-triyne-1,3-diol
1,3-Dihydroxy-6(𝐸)-
tetradecene-8,10,12-
triyne
OH
OH
Whole (Taiwan) [39–41]
13
(2𝑅,3𝐸,11𝐸)-3,11-
Tridecadiene-5,7,9-
triyne-1,2-diol
Safynol
OH
HO
Not found
(Egypt and
China)
[33, 35]
14
5,7,9,11-
Tridecatetrayne-1,2-
diol
1,2-Dihydroxytrideca-
5,7,9,11-tetrayne
HO
OH
Whole (Taiwan) [39, 40, 42]
15
(𝑅)-3,5,7,9,11-
Tridecapentayne-1,2-
diol
(𝑅)-1,2-
Dihydroxytrideca-
3,5,7,9,11-pentayne
HO
OH
Aerial (Japan) [43]
16
(4𝐸)-1-
(Hydroxymethyl)-4-
dodecene-6,8,10-triyn-
1-yl-𝛽-𝐷-
glucopyranoside
2-𝛽-𝐷-
Glucopyranose-1-
hydroxy-5(𝐸)-
tridecene-7,9,11-triyne
O
HO
H
OH
H
H
H
HOH
O
OH
HO
Aerial (USA);
whole (Taiwan);
leaves (Taiwan)
[15, 23, 24,
30, 41]
17
(4𝐸)-1-(2-
Hydroxylethyl)-4-
dodecene-6,8,10-triyn-
1-yl-𝛽-𝐷-
glucopyranoside
3-𝛽-𝐷-
Glucopyranose-1-
hydroxy-6(𝐸)-
tridecene-8,10,12-
triyne
O
HO
H
OH
H
H
H
HOH
O
OH
OH
Aerial (USA and
China); whole
(Taiwan); leaves
(Taiwan)
[15, 23, 24,
30, 41, 44]
18
3-Hydroxy-6-
tetradecene-8,10,12-
triynyl-𝛽-D-
glucopyranoside
𝛽-𝐷-
Glucopyranoyloxy-3-
hydroxy-6𝐸-
tetradecene-8,10,12-
triyne
OH
O
OH
H
OH
H
H
H
HO H
O
HO
Whole (Mexico) [45]
19
1-(Hydroxymethyl)-
4,6,8,10-
dodecatetrayne-1-yl-𝛽-
𝐷-glucopyranoside
Cytopiloyne,
2-𝛽-𝐷-
Glucopyranose-1-
hydroxytrideca-
5,7,9,11-tetrayne
O
HO
H
OH
H
H
H
OHH
O
OH
OH
Whole
(Taiwan); leaves
(Taiwan)
[15, 20, 24]
20
2-𝑂-𝐷-
Glucosyltrideca-11𝐸-
en-3,5,7,9-tetrayn-1,2-
diol
OH
HO
O
HO
H
HO
H
H
H
H
O
OH
Leaves (Brazil) [46]
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21
(𝑅)-1-
(Hydroxymethyl)-
2,4,6,8,10-
dodecapentayn-1-yl-aˆ-
𝐷-glucopyranoside
2-𝛽-𝐷-
Glucopyranose-1-
hydroxytrideca-
3,5,7,9,11-pentayne
OH
O
OH
H
HO
H
H
H
HO
H
O
OH
Aerial (China
and Japan) [43, 44]
22
1-
[[(Carboxyacetyl)oxy]
methyl]4,6,8,10-
dodecatetraynyl-aˆ-𝐷-
glucopyranoside
O
O
OHH
HO
H
H
H
H
O
OH
O
OH
HO
O
Aerial (Japan) [47]
23
(4𝐸)-1-
[[(Carboxyacetyl)oxy]-
methyl]-4-dodecene-
6,8,10-triynyl-aˆ-D-
glucopyranoside
OH
OH
OH
O
O
H
HO
H
H
H
HO
H
O
O
O
Aerial (Japan) [47]
24
(4𝐸)-1-
[[(Carboxyacetyl)oxy]-
ethyl]-4-dodecene-
6,8,10-triynyl-aˆ-𝐷-
glucopyranoside
O
O
H
HO
H
H
H
HO
H
O
OH
OH
O
OH
O
Aerial (Japan) [47]
25 (5𝐸)-5-Heptene-1,3-diyn-1-yl-benzene
1-Phenylhepta-1,3-
diyn-5en Whole (Taiwan) [48]
26 7-Phenyl-2(𝐸)-heptene-4,6-diyn-1-ol
OH
Roots (not
stated); aerial
(China)
[34, 38]
27
7-Phenyl-2(𝐸)-
heptene-4,6-diyn-1-ol-
acetate
O
O
Roots not stated
and brazil [34, 49, 50]
28 7-Phenyl-4,6-heptadiyn-2-ol Pilosol A
OH
Whole
(Taiwan); aerial
(China)
[38, 48]
29 7-Phenylhepta-4,6-diyn-1,2-diol HO
OH
Aerial (China) [38]
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30 1,3,5-Heptatriyn-1-yl-benzene
1-Phenylhepta-1,3,5-
triyne
Leaves (not
stated); leaves of
tissue culture
(not stated);
aerial (Tanzania
and China);
whole (Taiwan);
roots (Brazil)
[34, 38, 48,
50–53]
31 7-Phenyl-2,4,6-heptatriyn-1-ol
HO
Leaves (not
stated) and
aerial (China)
[34, 38]
32 7-Phenyl-2,4,6-heptatriyn-1-ol-acetate O
O Leaves (not
stated) [34]
33
5-(2-Phenylethynyl)-2-
thiophene
methanol
S OH
Aerial (China) [38]
34
5-(2-Phenylethynyl)-
2𝛽-glucosylmethyl-
thiophene
S O
O
OHHO
H
OH
H
H
H
OH
H
O
Aerial (China) [38]
35
3-𝛽-𝐷-
Glucopyranosyl-1-
hydroxy-6(𝐸)-
tetradecene-8,10,12-
triyne
OH
OH
HOH
OH
OH
O
O
H
H
H
H
Leaves
(Cameroon) [54]
36
1-Phenyl-1,3-diyn-5-en-
7-ol-acetate O
O
Leaves (Brazil) [46]
that causes 50% lethality, of the hydroethanol extracts in
mice was 12.3 g/kg BW and 6.2 g/kg BW, respectively [61].
Ezeonwumelu et al. showed that oral delivery of the water
extract of the B. pilosa whole plant at 1 g/kg BW/day, once a
day, seems nontoxic in rats over 28 days in Wistar rats [62],
which is in line with our observations in rat [5]. Overall, these
data suggest that consumption of B. pilosa aqueous extract at
up to at 1 g/kg BW/day, once a day, is highly safe in rats. A
complete toxicology and drug-drug interaction of B. pilosa
with other drugs in humans are required prior to its further
medical use.
6. Conclusions
B. pilosa is aworldwide plant andwidely used as folk remedies
and foods. It has long used to treat diabetes in different
continents. However, a comprehensive up-to-date review of
research on B. pilosa for diabetes has hitherto been not avail-
able. In this paper, scientific studies on the use of B. pilosa as
an anti-diabetic remedy have been summarized and critically
discussed from botanical, phytochemical, pharmacological,
and toxicological aspects.Thirty-six polyynes identified from
this plant were identified and three of which were showed
to treat both T1D and T2D. The anti-diabetic utility of B.
pilosa and its modes of action in relation to its known
polyynes were discussed herein. Cautions should be taken in
the anti-diabetic use of B. pilosa alone and in combination
with other medicines since its overdose may cause dramatic
hypoglycemia.
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Table 5: Polyynes of 𝐵. pilosa and their biological activities.
S.
number Name Classification
Molecular
formula Biological activities
11 1,2-Dihydroxy-5(𝐸)-tridecene-7,9,11-triyne [55] Polyyne C13H14O2
Antiangiogenetic [55]
Antiproliferative [55]
12 1,3-Dihydroxy-6(𝐸)-tetradecene-8,10,12-triyne [56] Polyyne C14H16O2 Antiangiogenetic [56]
14 1,2-Dihydroxytrideca-5,7,9,11-tetrayne [56] Polyyne C13H12O2 Antiangiogenetic [56]
15 (𝑅)-1,2-dihydroxytrideca-3,5,7,9,11-pentayne [43] Polyyne C13H8O2
Antimalarial [43]
Antibacterial [43]
6 2-𝛽-𝐷-Glucopyranose-1-hydroxy-5(𝐸)-tridecene-7,9,11-
triyne [54]
Polyyne C19H24O7
Antidiabetic [54]
Anti-inflammatory [57]
Antimalarial [43]
Antibacterial [43]
30 1-Phenylhepta-1,3,5-triyne [58] Polyyne C13H8
Antimicrobial [59]
Antimalarial [9]
Cytotoxic [9]
Antifungal [60]
35 3-𝛽-𝐷-Glucopyranosyl-1-hydroxy-6(𝐸)-tetradecene-8,10,12-
triyne [54]
Polyyne C20H26O7
Antidiabetic [54]
Anti-inflammatory [57]
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